Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Article Details
- CitationCopy to clipboard
Sonpavde G, Hutson TE
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Curr Oncol Rep. 2007 Mar;9(2):115-9.
- PubMed ID
- 17288876 [ View in PubMed]
- Abstract
Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Pazopanib Mast/stem cell growth factor receptor Kit Protein Humans YesInhibitorDetails Pazopanib Platelet-derived growth factor receptor alpha Protein Humans YesInhibitorDetails Pazopanib Platelet-derived growth factor receptor beta Protein Humans YesInhibitorDetails Pazopanib Vascular endothelial growth factor receptor 1 Protein Humans YesInhibitorDetails Pazopanib Vascular endothelial growth factor receptor 2 Protein Humans YesInhibitorDetails Pazopanib Vascular endothelial growth factor receptor 3 Protein Humans YesNot Available Details